von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease

Blood

Volumn 125, Issue 19, 2015, Pages 3006-3013

  Sanders, Yvonne V ^a   Groeneveld, Dafna ^b   Meijer, Karina ^c   Fijnvandraat, K ^k   Cnossen, Marjon H ^e   Van Der Bom, Johanna G ^b,f   Coppens, M ^g,k   De Meris, Joke ^h   Laros van Gorkom, Britta A P ⁱ   Mauser Bunschoten, Eveline P ^j   Leebeek, F W G ^a   Eikenboom, Jeroen ^b   Kors, A ^l   Zweegman, S ^l   De Meris, J ^h   Goverde, G J ^m   Jonkers, M H ^m   Dors, N ⁿ   Nijziel, M R ^o   Meijer, K ^c   Tamminga, R Y J ^c   Van Der Linden, P W ^p   Ypma, P F ^q   Van Der Bom, J G ^b   Smiers, F J W ^b   Granzen, B ^r   Hamulyak K ^r   Brons, P ⁱ   Laros Van Gorkom, B A P ⁱ   Cnossen, M H ^a   Sanders, Y V ^a   Van Creveld, ^a   Mauser Bunschoten, E P ^s   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d EMMA CHILDREN S HOSPITAL   (Netherlands)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^f SANQUIN RESEARCH   (Netherlands)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h Netherlands Hemophilia Patients Society   (Netherlands)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^k ACADEMIC MEDICAL CENTER   (Netherlands)

^l VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^m AMPHIA HOSPITAL   (Netherlands)

ⁿ CATHARINA HOSPITAL   (Netherlands)

^o MÁXIMA MEDICAL CENTER   (Netherlands)

^p Department of Orthopaedic Surgery   (Netherlands)

^q HAGA HOSPITAL   (Netherlands)

^r MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^s UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR; PROTEIN PRECURSOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CHILD; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NULL ALLELE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; VON WILLEBRAND DISEASE; CLASSIFICATION; CROSS-SECTIONAL STUDY; FOLLOW UP; GENETICS; INFANT; METABOLISM; MIDDLE AGED; MUTATION; NETHERLANDS; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; VERY ELDERLY; VON WILLEBRAND DISEASES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; NETHERLANDS; PHENOTYPE; PROGNOSIS; PROTEIN PRECURSORS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84929167540     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-603241     Document Type: Article

References (32)

1. Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost. 2003;1(7):1335-1342.
2. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest. 1973;52(11):2757-2764.
3. Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J. 1986;5(8):1839-1847.
4. Wagner DD, Mayadas T, Marder VJ. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol. 1986;102(4):1320-1324.
5. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424.
6. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood. 1994;83(12):3536-3544.
7. Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood. 1996;88(8):2951-2958.
8. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood. 2006;108(10):3344-3351.
9. Eikenboom JC, Castaman G, Kamphuisen PW, Rosendaal FR, Bertina RM. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. Thromb Haemost. 2002;87(2):252-257.
10. Lenting PJ, VAN Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost. 2007;5(7):1353-1360.
11. Sadler JE, Budde U, Eikenboom JC, et al Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114.
12. Eikenboom J, Federici AB, Dirven RJ, et al; MCMDM-1VWD Study Group. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood. 2013;121(12):2336-2339.
13. de Wee EM, Leebeek FW, Eikenboom JC. Diagnosis and management of von Willebrand disease in The Netherlands. Semin Thromb Hemost. 2011;37(5):480-487.
14. de Wee EM, Sanders YV, Mauser-Bunschoten EP, et al; WiN study group. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost. 2012;108(4):683-692.
15. de Wee EM, Mauser-Bunschoten EP, Van Der Bom JG, et al Win Study Group. Health-related quality of life among adult patients with moderate and severe von Willebrand disease. J Thromb Haemost. 2010;8(7):1492-1499.
16. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4(4):766-773.
17. Tosetto A, Castaman G, Rodeghiero F. Bleeding scores in inherited bleeding disorders: clinical or research tools? Haemophilia. 2008;14(3):415-422.
18. Salem RO, Van Cott EM. A new automated screening assay for the diagnosis of von Willebrand disease. Am J Clin Pathol. 2007;127(5):730-735.
19. Chen D, Tange JI, Meyers BJ, Pruthi RK, Nichols WL, Heit JA. Validation of an automated latex particle-enhanced immunoturbidimetric von Willebrand factor activity assay. J Thromb Haemost. 2011;9(10):1993-2002.
20. Caron C, Mazurier C, Goudemand J. Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents. Br J Haematol. 2002;117(3):716-718.
21. Casonato A, Pontara E, Sartorello F, et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood. 2002;99(1):180-184.
22. Schooten CJ, Tjernberg P, Westein E, et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost. 2005;3(10):2228-2237.
23. Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008;111(7):3531-3539.
24. Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008;111(10):4979-4985.
25. Jacobi PM, Gill JC, Flood VH, Jakab DA, Friedman KD, Haberichter SL. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood. 2012;119(19):4543-4553.
26. Casonato A, Daidone V, Padrini R. Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease. Semin Thromb Hemost. 2011;37(5):456-463.
27. Stoddart JH Jr, Andersen J, Lynch DC. Clearance of normal and type 2A von Willebrand factor in the rat. Blood. 1996;88(5):1692-1699.
28. Casonato A, Gallinaro L, Cattini MG, et al. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. Haematologica. 2010;95(8):1366-1372.
29. Casari C, Du V, Wu YP, et al. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia. Blood. 2013;122(16):2893-2902.
30. Madabhushi SR, Shang C, Dayananda KM, et al. von Willebrand factor (VWF) propeptide binding to VWF D′D3 domain attenuates platelet activation and adhesion. Blood. 2012;119(20):4769-4778.
31. Peake IR, Goodeve AC. Genetic testing for von Willebrand disease: the case for. J Thromb Haemost. 2010;8(1):13-16.
32. Robertson JD, Yenson PR, Rand ML, et al. Expanded phenotype-genotype correlations in a pediatric population with type 1 von Willebrand disease. J Thromb Haemost. 2011;9(9):1752-1760.